Oric Pharmaceuticals, Inc. (ORIC) Q3 2025 10-Q Quarterly Report
Oric Pharmaceuticals, Inc. (ORIC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Oric Pharmaceuticals, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Market conditions risk of banking insolvency triggered by 2023 Silicon Valley Bank receivership causing temporary funds inaccessibility
- • Most material update: Net loss $99M for nine months ended Sept 30, 2025; accumulated deficit $661.7M, reflecting ongoing significant losses
Get deeper insights on Oric Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.